Microneedle Patch for Peanut Allergies Begins Clinical Trials | RT

Moonlight Therapeutics' microneedle patch for peanut allergy desensitisation has entered phase 1 clinical trials at Children's Healthcare of Atlanta, delivering controlled peanut protein doses through the skin in three minutes. The device, cleared by the FDA in late 2025, is designed for home use and targets a market of 1.2m+ allergic children in the US.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.